2011
DOI: 10.1159/000320693
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Value of Serum Neopterin, Tissue Polypeptide-Specific Antigen and CA19-9 Levels in Differential Diagnosis between Pancreatic Cancer and Chronic Pancreatitis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
10
0

Year Published

2012
2012
2023
2023

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 22 publications
(11 citation statements)
references
References 19 publications
1
10
0
Order By: Relevance
“…Furthermore, MIC-1 showed a significant difference in levels between PC and CP patients ( P = 0.043), with no noticeable difference observed for NGAL or CA19-9 ( P >0.10). Interestingly, these results are similar to available data from previously published studies evaluating these markers in patient sera (Supplementary Table 4) [8, 9, 21–23]. …”
Section: Discussionsupporting
confidence: 90%
“…Furthermore, MIC-1 showed a significant difference in levels between PC and CP patients ( P = 0.043), with no noticeable difference observed for NGAL or CA19-9 ( P >0.10). Interestingly, these results are similar to available data from previously published studies evaluating these markers in patient sera (Supplementary Table 4) [8, 9, 21–23]. …”
Section: Discussionsupporting
confidence: 90%
“…Therefore, elevated concentrations of neopterin in body fluids reflect cellular immune activation involving T cells and an endogenous release of INF‐γ . Studies have observed increased levels of neopterin in patients with malignant diseases such as lung, breast, and pancreatic cancer . The extent of neopterin elevation depends on tumor type and stage, and neopterin has been proposed as a potential biomarker of cancer diagnosis and prognosis .…”
mentioning
confidence: 99%
“…With regard to serum CA19-9, its level was dramatically elevated in PC group (253.3 [28] U/mL) at P G 0.001. Prominent IR was found in patients with PC (serum insulin was 17.9 [1.5] HU/mL and HOMA-IR median was 10) compared with diabetic patients (serum insulin was 14.4 [0.8] HU/mL and HOMA-IR median was 6.9) at P G 0.05 and nondiabetic controls (serum insulin was 7.1 [0.4] HU/mL and HOMA-IR median was 1.6) at P G 0.001.…”
Section: Resultsmentioning
confidence: 90%